Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESTA NYSE:GKOS NASDAQ:LQDA NYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$91.90-0.2%$83.63$33.35▼$96.99$2.71B1.06483,124 shs393,023 shsGKOSGlaukos$151.66-0.2%$136.27$73.16▼$161.53$8.92B0.75631,351 shs1.14 million shsLQDALiquidia$86.82+2.8%$72.31$16.82▼$91.10$7.51B0.551.40 million shs1.17 million shsSTVNStevanato Group€20.19+2.0%€18.48€12.89▼€28.00€6.11B0.78545,210 shs469,100 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-0.24%-1.41%+4.21%+43.01%+117.17%GKOSGlaukos-0.87%-2.23%+5.33%+27.03%+61.30%LQDALiquidia-2.09%+9.52%+8.00%+124.22%+330.71%STVNStevanato Group+0.41%+2.86%+11.26%+21.48%-24.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$91.90-0.2%$83.63$33.35▼$96.99$2.71B1.06483,124 shs393,023 shsGKOSGlaukos$151.66-0.2%$136.27$73.16▼$161.53$8.92B0.75631,351 shs1.14 million shsLQDALiquidia$86.82+2.8%$72.31$16.82▼$91.10$7.51B0.551.40 million shs1.17 million shsSTVNStevanato Group€20.19+2.0%€18.48€12.89▼€28.00€6.11B0.78545,210 shs469,100 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs-0.24%-1.41%+4.21%+43.01%+117.17%GKOSGlaukos-0.87%-2.23%+5.33%+27.03%+61.30%LQDALiquidia-2.09%+9.52%+8.00%+124.22%+330.71%STVNStevanato Group+0.41%+2.86%+11.26%+21.48%-24.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESTAEstablishment Labs 2.67Moderate Buy$90.43-1.60% DownsideGKOSGlaukos 2.73Moderate Buy$155.232.35% UpsideLQDALiquidia 2.82Moderate Buy$86.18-0.74% DownsideSTVNStevanato Group 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ESTA, GKOS, LQDA, and STVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026GKOSGlaukos UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral$150.007/28/2026GKOSGlaukos UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Neutral7/24/2026LQDALiquidia Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$130.007/24/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.007/24/2026LQDALiquidia Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$129.007/24/2026LQDALiquidia StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$130.007/23/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $130.007/17/2026GKOSGlaukos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026LQDALiquidia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026GKOSGlaukos Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$170.00 ➝ $175.007/16/2026STVNStevanato Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESTAEstablishment Labs$211.08M12.81N/AN/A$0.81 per share113.46GKOSGlaukos$507.44M17.55N/AN/A$11.42 per share13.28LQDALiquidia$158.32M48.77N/AN/A$0.51 per share170.24STVNStevanato Group€1.34B4.56€0.90 per share22.44€5.55 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESTAEstablishment Labs-$51.06M-$1.49N/A656.43N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)GKOSGlaukos-$187.69M-$3.28N/A329.70N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)LQDALiquidia-$68.92M$0.14620.1916.35N/A7.74%46.82%7.06%8/11/2026 (Estimated)STVNStevanato Group€158.21M€0.5934.2224.331.7711.76%10.27%6.08%8/4/2026 (Confirmed)Latest ESTA, GKOS, LQDA, and STVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026LQDALiquidia$0.7580N/AN/AN/A$168.48 millionN/A8/6/2026Q2 2026ESTAEstablishment Labs-$0.34N/AN/AN/A$65.79 millionN/A7/29/2026Q2 2026GKOSGlaukos-$0.2235N/AN/AN/A$150.99 millionN/A5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/8/2026Q1 2026STVNStevanato Group€0.12€0.11-€0.01€0.10N/A€273.57 million5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million4/29/2026Q1 2026GKOSGlaukos-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESTAEstablishment LabsN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESTAEstablishment Labs16.822.961.91GKOSGlaukos0.105.434.73LQDALiquidia1.182.222.03STVNStevanato Group0.211.631.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESTAEstablishment Labs72.91%GKOSGlaukos99.04%LQDALiquidia64.54%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipESTAEstablishment Labs9.99%GKOSGlaukos5.90%LQDALiquidia25.60%STVNStevanato GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESTAEstablishment Labs1,00429.43 million26.49 millionOptionableGKOSGlaukos1,09458.73 million55.27 millionOptionableLQDALiquidia5088.93 million66.16 millionOptionableSTVNStevanato Group6,010302.84 millionN/AOptionableESTA, GKOS, LQDA, and STVN HeadlinesRecent News About These CompaniesStevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026July 21, 2026 | businesswire.comStevanato Group S.p.A. $STVN Stock Holdings Lifted by Van Berkom & Associates Inc.July 20, 2026 | marketbeat.comRoubaix Capital LLC Has $5.30 Million Holdings in Stevanato Group S.p.A. $STVNJuly 19, 2026 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 18, 2026 | americanbankingnews.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 18, 2026 | marketbeat.comKornitzer Capital Management Inc. KS Purchases Shares of 135,000 Stevanato Group S.p.A. $STVNJuly 13, 2026 | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Reduces Stake in Stevanato Group S.p.A. $STVNJuly 5, 2026 | marketbeat.comConestoga Capital Advisors LLC Has $116.76 Million Stock Position in Stevanato Group S.p.A. $STVNJuly 2, 2026 | marketbeat.comStevanato Group (NYSE:STVN) Shares Gap Up - What's Next?July 1, 2026 | marketbeat.comTimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)July 1, 2026 | insidermonkey.comTimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)July 1, 2026 | finance.yahoo.comStevanato Group (NYSE:STVN) Director Sells €25,515.37 in StockJune 27, 2026 | insidertrades.comTD Cowen Initiates a Buy Rating on Stevanato Group (STVN)June 19, 2026 | theglobeandmail.comSTVN Share News TodayJune 19, 2026 | uk.investing.comStevanato Group (STVN) Stock Valuation Check After Recent Share Price WeaknessJune 14, 2026 | finance.yahoo.comIs Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comStevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling UpsideJune 11, 2026 | seekingalpha.comStevanato Group Posts Strong Q1 2026 Growth and Accelerates Cartridge Capacity ExpansionJune 8, 2026 | theglobeandmail.comStevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight ManagementJune 8, 2026 | joplinglobe.comJStevanato Group Posts Q1 2026 Revenue Growth and Reaffirms Full-Year GuidanceJune 8, 2026 | theglobeandmail.comStevanato Group Introduces Deoraâ„¢, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight ManagementJune 8, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNew Stock Price Highs Are on the Menu for Darden RestaurantsBy Thomas Hughes | June 29, 2026Confidence Is Back, But Earnings Show the Consumer Is Being PickyBy Jessica Mitacek | July 21, 2026Burger King’s Turnaround Is Putting Restaurant Brands Back in FocusBy Peter Frank | July 1, 2026Toast’s Comeback Story Is Getting Harder for Wall Street to IgnoreBy Chris Markoch | July 16, 2026The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the BetBy Nathan Reiff | July 17, 2026ESTA, GKOS, LQDA, and STVN Company DescriptionsEstablishment Labs NASDAQ:ESTA$91.90 -0.20 (-0.22%) Closing price 04:00 PM EasternExtended Trading$91.86 -0.05 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Glaukos NYSE:GKOS$151.66 -0.25 (-0.16%) Closing price 03:59 PM EasternExtended Trading$151.55 -0.11 (-0.07%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Liquidia NASDAQ:LQDA$86.82 +2.40 (+2.84%) Closing price 04:00 PM EasternExtended Trading$87.36 +0.55 (+0.63%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Stevanato Group NYSE:STVN€20.19 +0.39 (+1.98%) Closing price 03:59 PM EasternExtended Trading€20.16 -0.03 (-0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
